Bavarian Nordic (BATS-CHIXE:BAVAC) - Cotización, noticias y análisis

Resumen de acción BAVAC

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas.

BAVAC fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 92.4% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 5.94%

Los beneficios aumentaron un 227.1% el pasado año

Análisis de riesgos

Acciones altamente ilíquidas

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Bavarian Nordic A/S

Genus

LSE:GNS

UK£1.2b

Bioventix

AIM:BVXP

UK£228.4m

HUTCHMED (China)

AIM:HCM

UK£3.0b

Ergomed

AIM:ERGO

UK£701.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.156.90
52 Week High	kr.214.40
52 Week Low	kr.135.38
Beta	1.33
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-13.81%
3 Year Change	-39.54%
5 Year Change	14.99%
Change since IPO	142.32%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BAVAC	GB Biotechs	Mercado GB
7D	0%	0.9%	2.5%
1Y	-13.8%	-22.3%	6.1%

Rentabilidad vs. Industria: BAVAC superó al sector UK Biotechs , que obtuvo un rendimiento del -27.7% el año pasado.

Rentabilidad vs. Mercado: BAVAC obtuvo unos resultados inferiores a los del mercado UK, que fue del 0.6% el año pasado.

Volatilidad de los precios

Is BAVAC's price volatile compared to industry and market?
BAVAC volatility
BAVAC Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: BAVAC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BAVAC en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	1,379	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas. La empresa ofrece vacunas no replicantes contra la viruela y la viruela del mono con los nombres IMVAMUNE, IMVANEX y JYNNEOS; vacuna antirrábica para uso humano con el nombre Rabipur/RabAvert; vacuna contra la encefalitis transmitida por garrapatas con el nombre Encepur; y vacuna contra el ébola con el nombre MVABEA. También está desarrollando MVA-BN para el tratamiento de la viruela; MVA-BN RSV, que se encuentra en ensayos clínicos de fase III para el tratamiento del virus respiratorio sincitial; ABNCoV2 que ha completado el ensayo clínico de fase III para el tratamiento del SARS-CoV-2.

Resumen de fundamentos de Bavarian Nordic A/S

¿Cómo se comparan los beneficios e ingresos de Bavarian Nordic con su capitalización de mercado?
Estadísticas fundamentales de BAVAC
Capitalización bursátil	kr.12.70b
Beneficios(TTM)	kr.984.37m
Ingresos (TTM)	kr.6.64b

12.9x

Ratio precio-beneficio (PE)

1.9x

Ratio precio-ventas (PS)

¿Está BAVAC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BAVAC
Ingresos	kr.6.64b
Coste de los ingresos	kr.2.04b
Beneficio bruto	kr.4.60b
Otros gastos	kr.3.62b
Beneficios	kr.984.37m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Aug 22, 2024

Beneficios por acción (BPA)	12.63
Margen bruto	69.29%
Margen de beneficio neto	14.82%
Ratio deuda/patrimonio	0.2%

¿Cómo se ha desempeñado BAVAC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BAVAC

Recompensas

Análisis de riesgos

Competidores de Bavarian Nordic A/S

LSE:GNS

UK£1.2b

AIM:BVXP

UK£228.4m

AIM:HCM

UK£3.0b

AIM:ERGO

UK£701.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Recent updates

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

High number of new directors

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

High number of new directors